Buscar.
Resultados de la búsqueda 49
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China) Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration）approved AmoyDx Super-ARMS® EGFR mutation test kit
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
Noticias & eventos
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
Recently Boehringer Ingelheim launched a Phase II study of Afatinib (Identifier: NCT02597946) to evaluate its efficacy and safety in advanced patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
Noticias & eventos
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017
· Merck is the first pharmaceutical company to collaborate with multiple
Noticias & eventos
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
Noticias & eventos
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
Super-ARMS® EGFR Mutation Detection Kit
The best solution for Plasma EGFR Mutation Testing
PRODUCTOS
EGFR 29 Mutations Detection Kit
PRODUCTOS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTOS
KRAS Mutation Detection Kit
PRODUCTOS
KRAS/NRAS Mutations Detection Kit
PRODUCTOS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTOS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTOS
HER-2 Gene Amplification Analysis Kit
PRODUCTOS
P-EGFR-L2-01 Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
Descargar
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
Descargar
EGFR-L2-06 EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with
Descargar
EGFR-L2-05 Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination
Descargar
EGFR-L2-04 Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays
Descargar
EGFR-L2-03 EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma
Descargar
EGFR-L2-02 Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma A case report
Descargar
EGFR-L2-01 Molecular pathology in lung cancer a guide to the techniques used in clinical practice
Descargar
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
Descargar
P-T790M-L1-01 Detection of EGFR T790M in Asia-Pacific patients with EGFR mutation-positive advanced NSCLC circulating tumour DNA
Descargar
P-EGFR-L1-03 Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung
Descargar
P-EGFR-L1-02 Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC
Descargar
P-EGFR-L1-01 Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients
Descargar
HER2-L1-01 Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Descargar
EGFR-L1-06 EML4-ALK-L1-01 Intratumoral Heterogeneity of ALK-Rearranged and ALK_EGFR Coaltered Lung Adenocarcinoma
Descargar
EGFR-L1-05 Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS
Descargar
EGFR-L1-04 Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Descargar
EGFR-L1-03 ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
Descargar
EGFR-L1-02 Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
Descargar
EGFR-L1-01 The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation
Descargar
Relationship between KRAS and EGFR gene mutations and clinicopathological features in patients with non-small cell lung cancer in China
Zhang Jiexia, Li Shiyue, Zhan Yangqing, Ouyang Ming
Descargar
no más...
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China) Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration）approved AmoyDx Super-ARMS® EGFR mutation test kit
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
Noticias & eventos
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
Recently Boehringer Ingelheim launched a Phase II study of Afatinib (Identifier: NCT02597946) to evaluate its efficacy and safety in advanced patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
Noticias & eventos
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017
· Merck is the first pharmaceutical company to collaborate with multiple
Noticias & eventos
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
Noticias & eventos
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
no más...
Super-ARMS® EGFR Mutation Detection Kit
The best solution for Plasma EGFR Mutation Testing
PRODUCTOS
EGFR 29 Mutations Detection Kit
PRODUCTOS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTOS
KRAS Mutation Detection Kit
PRODUCTOS
KRAS/NRAS Mutations Detection Kit
PRODUCTOS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTOS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTOS
HER-2 Gene Amplification Analysis Kit
PRODUCTOS
no más...
P-EGFR-L2-01 Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
Descargar
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
Descargar
EGFR-L2-06 EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with
Descargar
EGFR-L2-05 Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination
Descargar
EGFR-L2-04 Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays
Descargar
EGFR-L2-03 EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma
Descargar
EGFR-L2-02 Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma A case report
Descargar
EGFR-L2-01 Molecular pathology in lung cancer a guide to the techniques used in clinical practice
Descargar
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
Descargar
P-T790M-L1-01 Detection of EGFR T790M in Asia-Pacific patients with EGFR mutation-positive advanced NSCLC circulating tumour DNA
Descargar
P-EGFR-L1-03 Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung
Descargar
P-EGFR-L1-02 Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC
Descargar
P-EGFR-L1-01 Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients
Descargar
HER2-L1-01 Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Descargar
EGFR-L1-06 EML4-ALK-L1-01 Intratumoral Heterogeneity of ALK-Rearranged and ALK_EGFR Coaltered Lung Adenocarcinoma
Descargar
EGFR-L1-05 Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS
Descargar
EGFR-L1-04 Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Descargar
EGFR-L1-03 ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
Descargar
EGFR-L1-02 Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
Descargar
EGFR-L1-01 The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation
Descargar
Relationship between KRAS and EGFR gene mutations and clinicopathological features in patients with non-small cell lung cancer in China
Descargar
no más...